Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Viatris (VTRS)

NASDAQ: VTRS · Pharmaceuticals · Canonsburg, PA

Our rating: Neutral

Neutral reaffirmed at $19.91, moderate conviction, November 6, 2026.

Breaks if: The Neutral call moves Positive if reported free cash flow for any trailing twelve-month period clears $2.1B while year-over-year revenue decline narrows to 1% or less, indicating the erosion is plateauing and cash conversion is strengthening. It moves Cautious if trailing twelve-month free cash flow falls below $1.4B — a drop of roughly one quarter from current levels — signaling that revenue attrition is now flowing through to the cash line and the core yield thesis has cracked.

Key figures

Market value$22.5B
Revenue, last 12 months$14.7B
Net income, last 12 monthsn/a
Free cash flow, last 12 months$2.1B
Price to earningsn/a
Free cash flow yield9.4%
Dividend yield2.4%
Operating margin−0.0%
Return on equityn/a
Beta to the S&P 5000.72
Volatility, annualized33.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$3.7B−0.3%$-0.28$814M
June 30, 2026$3.7B5.0%$-0.10$329M
March 31, 2026$3.5B8.2%$0.15$348M
December 31, 2025$3.7B5.0%$-0.30$619M
September 30, 2025$3.7B0.3%$-0.11$658M
June 30, 2025$3.6B−5.7%$0.00$167M
March 31, 2025$3.2B−11.2%$-2.55$493M
December 31, 2024$3.5B−8.1%$-0.43$342M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

10 ledger entries and 33 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.